Diagnostic value of bone and tumour markers in patients with malignant diseases

Anticancer Research

Volumn 23, Issue 2 A, 2003, Pages 987-990

  Oremek, G M ^a   Weis, A ^a   Sapoutzis, N ^a   Sauer Eppel, H ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Bone markers; Skeletal metastases; Tumour markers

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; BETA CROSSLAP; BIOCHEMICAL MARKER; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

BLOOD LEVEL; BONE METASTASIS; BONE REMODELING; BONE SCINTISCANNING; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GROWTH; COLON CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HUMAN; LIVER CARCINOMA; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE NEOPLASMS; BREAST NEOPLASMS; COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037524315     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Seibel MJ and Woitge HW: Biochemical markers of bone metabolism. Clin Lab 45: 237-256, 1999.
2. Woitge HW and Pecherstorfer M: Novel serum markers of bone resorption. J Bone Miner Res 14: 792-80, 1999.
3. Janckila AJ, Takahashi K, Sun SZ and Yam LT: Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 47: 74-80; 2001.
4. Fischer M et al: New aspects of radionuclide therapy in metastatic bone pain. Anticancer Res 20: 5183, 2000.
5. Stieber P et al: Sensible use of tumor markers. Lab Med 25: 327-336, 2001.
6. Oremek GM, Kramer W, Seiffert UB and Jonas D: Diagnostic value of skeletal AP and PSA with respect to skeletal scintigram in patients with prostatic disease. Anticancer Res 17: 3035, 1997.
7. Reiter W et al: Tumor markers in prostate cancer. J Lab Med 25: 337-342, 2001.
8. Hammerer P and Graeffen M et al: Analysis of molecular isoforms of PSA and their ratios in men with biochemical progression of prostate carcinoma. Anticancer Res 20: 5253, 2000.
9. Klapdor R and Fenner C: Efficacy as third/fourth line therapy in advanced pancreatic cancer. Anticancer Res 20: 5209, 2000.
10. Holubec JR, Topolcan O et al: The significance of CEA, CA 19-9 and CA 72-4 in the detection of colorectal carcinoma recurrence. Anticancer Res 20: 5237, 2000.
11. Reiter W and Stieber P et al: Multivariante analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 20: 5195, 2000.
12. Untch M, Sauer A and Stieber P: Tumor markers in breast cancer. J Lab Med 25: 343-352, 2001.
13. Demers ML, Costa L and Lipton A: Biochemical Markers and Skeletal Metastases. Cancer 88: 2919-2926, June 15, 2000.